[go: up one dir, main page]

ATE389401T1 - Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung - Google Patents

Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung

Info

Publication number
ATE389401T1
ATE389401T1 AT02713446T AT02713446T ATE389401T1 AT E389401 T1 ATE389401 T1 AT E389401T1 AT 02713446 T AT02713446 T AT 02713446T AT 02713446 T AT02713446 T AT 02713446T AT E389401 T1 ATE389401 T1 AT E389401T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions containing
cancer treatment
preparing pharmaceutical
epothilone analogs
Prior art date
Application number
AT02713446T
Other languages
English (en)
Inventor
Rebanta Bandyopadhyay
Timothy Malloy
Andrea Panaggio
Krishnaswamy Raghavan
Sailesh Varia
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28678063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE389401(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE389401T1 publication Critical patent/ATE389401T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02713446T 2001-01-25 2002-01-22 Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung ATE389401T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000801P 2001-05-11 2001-05-11

Publications (1)

Publication Number Publication Date
ATE389401T1 true ATE389401T1 (de) 2008-04-15

Family

ID=28678063

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713446T ATE389401T1 (de) 2001-01-25 2002-01-22 Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung

Country Status (25)

Country Link
US (1) US6670384B2 (de)
EP (2) EP1938821B1 (de)
KR (1) KR100851719B1 (de)
CN (1) CN100341505C (de)
AR (1) AR032409A1 (de)
AT (1) ATE389401T1 (de)
BG (1) BG66494B1 (de)
BR (1) BRPI0206509B8 (de)
CY (1) CY1108114T1 (de)
CZ (1) CZ20032021A3 (de)
DE (1) DE60225666T2 (de)
DK (1) DK1353668T3 (de)
EE (1) EE05301B1 (de)
ES (1) ES2304240T3 (de)
HK (2) HK1065946A1 (de)
HU (1) HU229349B1 (de)
IS (1) IS2865B (de)
NO (1) NO20130070L (de)
NZ (1) NZ526870A (de)
PE (1) PE20020734A1 (de)
PT (1) PT1353668E (de)
SK (1) SK288098B6 (de)
TW (1) TWI342211B (de)
UY (1) UY27137A1 (de)
YU (1) YU58203A (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (de) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthese von Epitholonen, Zwischenprodukte, Analoga und ihre Verwendung
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
MXPA03006485A (es) * 2001-01-25 2003-09-22 Bristol Myers Squibb Co Formulacion parenteral que contiene analogos de epotilona.
EP1385529A4 (de) 2001-02-20 2007-05-09 Bristol Myers Squibb Co Behandlung refraktärer tumoren mit epothilon-derivativen
SK11082003A3 (sk) 2001-03-14 2004-08-03 Bristol-Myers Squibb Company Kombinácia analógov epotilónu a chemoterapeutických činidiel na liečenie proliferatívnych ochorení
US7211593B2 (en) * 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
ES2306278T3 (es) * 2004-11-18 2008-11-01 Bristol-Myers Squibb Company Perla enterica recubierta que comprende ixabepilona.
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
EP1674098A1 (de) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
EP1856255A4 (de) 2005-02-11 2010-01-27 Univ Southern California Verfahren zur expression von proteinen über disulfidbrücken
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130501A2 (en) 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP2571525A4 (de) 2010-05-18 2016-04-27 Cerulean Pharma Inc Zusammensetzungen und verfahren zur behandlung von autoimmun- und anderen erkrankungen
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
PL401116A1 (pl) * 2012-10-09 2014-04-14 Ryszka Florian Farmaceutyczny Zakład Naukowo-Produkcyjny Biochefa Kompozycja dodawana do płynów infuzyjnych
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
EP4087545A1 (de) 2020-01-10 2022-11-16 R-Pharm US Operating LLC Zusammensetzungen von ixabepilon
US20230048901A1 (en) * 2020-09-02 2023-02-16 Beijing Biostar Pharmaceuticals Co., Ltd. Solid oral formulation of utidelone

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
PT1367057E (pt) 1996-11-18 2008-12-04 Biotechnolog Forschung Gmbh Epotilonas e e f
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (de) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthese von Epitholonen, Zwischenprodukte, Analoga und ihre Verwendung
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CZ298027B6 (cs) 1997-02-25 2007-05-30 Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
WO1999003848A1 (de) 1997-07-16 1999-01-28 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
JP4644364B2 (ja) 1998-02-05 2011-03-02 ノバルティス アーゲー エポシロン組成物
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
KR20070087132A (ko) 1998-11-20 2007-08-27 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법및 물질
WO2000037473A1 (en) 1998-12-22 2000-06-29 Novartis Ag Epothilone derivatives and their use as antitumor agents
AU3156700A (en) 1999-02-18 2000-09-04 Schering Aktiengesellschaft 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
HK1065946A1 (en) 2005-03-11
EP1938821A3 (de) 2009-02-18
CN100341505C (zh) 2007-10-10
SK8562003A3 (en) 2004-07-07
DK1353668T3 (da) 2008-06-30
DE60225666D1 (de) 2008-04-30
CN1496258A (zh) 2004-05-12
CZ20032021A3 (cs) 2004-05-12
TWI342211B (en) 2011-05-21
AR032409A1 (es) 2003-11-05
CY1108114T1 (el) 2014-02-12
US20020169190A1 (en) 2002-11-14
IS6891A (is) 2003-07-24
EE05301B1 (et) 2010-06-15
EP1938821A2 (de) 2008-07-02
HU229349B1 (en) 2013-11-28
HK1116339A1 (en) 2008-12-19
NZ526870A (en) 2005-11-25
BRPI0206509B8 (pt) 2021-05-25
EE200300320A (et) 2003-10-15
HUP0302726A2 (hu) 2003-11-28
IS2865B (is) 2014-02-15
PT1353668E (pt) 2008-06-30
SK288098B6 (sk) 2013-07-02
BG108112A (bg) 2004-11-30
EP1353668B1 (de) 2008-03-19
BRPI0206509B1 (pt) 2018-10-02
KR100851719B1 (ko) 2008-08-11
BR0206509A (pt) 2004-09-08
HUP0302726A3 (en) 2007-08-28
BG66494B1 (bg) 2015-06-30
KR20040048874A (ko) 2004-06-10
UY27137A1 (es) 2002-08-30
NO20130070L (no) 2003-09-04
DE60225666T2 (de) 2009-04-16
US6670384B2 (en) 2003-12-30
YU58203A (sh) 2006-08-17
ES2304240T3 (es) 2008-10-01
EP1353668A1 (de) 2003-10-22
PE20020734A1 (es) 2002-08-17
BRPI0206509A8 (pt) 2017-09-19
EP1938821B1 (de) 2016-03-30

Similar Documents

Publication Publication Date Title
ATE389401T1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
DE60311176D1 (de) Verfahren zur Herstellung von Vorrichtungen zur Entnahme von physiologischen Proben
DE50303749D1 (de) Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
DE60323192D1 (de) Verfahren zur Herstellung von Hydroxyalkylstärkederivaten
DE50212243D1 (de) Prozess zur herstellung von aryl-aryl gekoppelten verbindungen
DE60124482D1 (de) Verfahren zur Herstellung von Xylylendiamin
DE50201891D1 (de) Verfahren zur herstellung von 1-octen
DE60223070D1 (de) Verfahren zur herstellung von dihalogenadamantanen
DE60216507D1 (de) Verfahren zur herstellung von polyetherimiden
DE60219193D1 (de) Verfahren zur herstellung von silylorganomercaptanen
DE60208738D1 (de) Verfahren zur Herstellung von Chlorfluorpolyoxyalkylenolen
DE60202635D1 (de) Verfahren zur Herstellung von eine Methacryloxyfunktionellegruppe enthaltenden Organosiliziumverbindungen
DE60217423D1 (de) Verfahren zur Herstellung aromatischer Verbindungen
DE50311721D1 (de) Verfahren zur Herstellung von Aryl-aminopropanolen
DE60233589D1 (de) Verfahren zur herstellung von echinocandinderivaten
DE50210487D1 (de) Verfahren zur Herstellung von 1-Amino-4-hydroxyanthrachinonen
DE60002784D1 (de) Verfahren zur Herstellung von Alkylhalogensilanen
DE60216931D1 (de) Verfahren zur herstellung von bisphenol-a
DE60322356D1 (de) Verfahren zur herstellung von 2-aminoindanderivaten
DE602004002784D1 (de) Verfahren zur Herstellung von Polyvinylpyrrolidon-Pulver
DE60209171D1 (de) Verfahren zur Herstellung von Bromfluorenen
DE60300201D1 (de) Verfahren zur Herstellung von Polyetherpolyolen
DE60222081D1 (de) Verfahren zur Herstellung von linearen Organopolysiloxanen
DE60205521D1 (de) Verfahren zur Herstellung linearer Organohydrosiloxanen
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1353668

Country of ref document: EP